AstraZeneca PLC
Case Overview
58 Days Left to Seek Lead Plaintiff
Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 02/21/2025 |
Status: | Status: Investigating |
Company Name: | Company Name: AstraZeneca PLC |
Court: | Court: Central District of California |
Case Number: | Case Number: 2:24cv11021 |
Class Period: | Class Period: 02/23/2022 - 12/17/2024 |
Ticker: | Ticker: AZN |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Central District of California on behalf of those who acquired AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ:AZN) securities during the period from February 23, 2022, through December 17, 2024 (“the Class Period”). Investors have until February 21, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit.
On October 30, 2024, AstraZeneca posted an announcement on its website under the heading “AstraZeneca China President currently under investigation,” which stated the following: “Leon Wang, Executive Vice President International and AstraZeneca China President, is cooperating with an ongoing investigation by Chinese authorities.” On this news, the price of AstraZeneca shares declined by $2.39 per share, from $75.22 on October 29, 2024, to close at $72.83 on October 30, 2024.
Then, on November 5, 2024, Yicai Global published an article entitled “AstraZeneca Insurance Fraud Involves Dozens of Senior Executives in China, Sources Say.” The article alleged that to boost sales of the lung cancer drug, Tagrisso, “staff forged positive genetic testing reports to defraud the health insurance fund, even colluding with genetic testing companies to funnel benefits.” The article further alleged that, over the past three years, insurance fraud cases involving AstraZeneca have surfaced in Shenzhen as well as in the provinces of Fujian and Jiangxi, amounting to the largest fraud in China’s pharmaceutical sector in years. On the same day, Reuters published an article entitled “AstraZeneca shares fall on report of potential China probe fallout.” On this news, the price of AstraZeneca shares fell a further $5.16 per share, or approximately 7.2%, from $71.43 on November 4, 2024, to close at $66.27 on November 5, 2024.
Finally, on December 18, 2024, Financial Times published an article entitled “AstraZeneca insiders expect sales dip in China after arrest of local boss.”. The article stated that “AstraZeneca’s sales in China have been hit by the arrest of its country head, says company insiders, as local hospital shuns purchasing drugs from the company.”. The article further stated that the arrest of AstraZeneca China’s President was a “dramatic reversal of fortunes for AstraZeneca in China, where it is the largest foreign drugmaker by sales.” On this news, the price of AstraZeneca shares declined by $2.54 per share, from $67.18 per share on December 17, 2024, to close at $64.64 on December 18, 2024.
The complaint alleges that defendants, throughout the Class Period, made materially false and/or misleading statements and/or failed to disclose that: (1) AstraZeneca engaged in insurance fraud in China; (2) as a result, AstraZeneca faced heightened legal exposure in China, which eventually resulted in the AstraZeneca China President being detained by Chinese law enforcement authorities; (3) as a result, AstraZeneca understated its legal risks; and (4) the foregoing, once revealed, could materially harm AstraZeneca’s business activities in China.
On October 30, 2024, AstraZeneca posted an announcement on its website under the heading “AstraZeneca China President currently under investigation,” which stated the following: “Leon Wang, Executive Vice President International and AstraZeneca China President, is cooperating with an ongoing investigation by Chinese authorities.” On this news, the price of AstraZeneca shares declined by $2.39 per share, from $75.22 on October 29, 2024, to close at $72.83 on October 30, 2024.
Then, on November 5, 2024, Yicai Global published an article entitled “AstraZeneca Insurance Fraud Involves Dozens of Senior Executives in China, Sources Say.” The article alleged that to boost sales of the lung cancer drug, Tagrisso, “staff forged positive genetic testing reports to defraud the health insurance fund, even colluding with genetic testing companies to funnel benefits.” The article further alleged that, over the past three years, insurance fraud cases involving AstraZeneca have surfaced in Shenzhen as well as in the provinces of Fujian and Jiangxi, amounting to the largest fraud in China’s pharmaceutical sector in years. On the same day, Reuters published an article entitled “AstraZeneca shares fall on report of potential China probe fallout.” On this news, the price of AstraZeneca shares fell a further $5.16 per share, or approximately 7.2%, from $71.43 on November 4, 2024, to close at $66.27 on November 5, 2024.
Finally, on December 18, 2024, Financial Times published an article entitled “AstraZeneca insiders expect sales dip in China after arrest of local boss.”. The article stated that “AstraZeneca’s sales in China have been hit by the arrest of its country head, says company insiders, as local hospital shuns purchasing drugs from the company.”. The article further stated that the arrest of AstraZeneca China’s President was a “dramatic reversal of fortunes for AstraZeneca in China, where it is the largest foreign drugmaker by sales.” On this news, the price of AstraZeneca shares declined by $2.54 per share, from $67.18 per share on December 17, 2024, to close at $64.64 on December 18, 2024.
The complaint alleges that defendants, throughout the Class Period, made materially false and/or misleading statements and/or failed to disclose that: (1) AstraZeneca engaged in insurance fraud in China; (2) as a result, AstraZeneca faced heightened legal exposure in China, which eventually resulted in the AstraZeneca China President being detained by Chinese law enforcement authorities; (3) as a result, AstraZeneca understated its legal risks; and (4) the foregoing, once revealed, could materially harm AstraZeneca’s business activities in China.